Palleiko Benjamin L.'s most recent trade in KalVista Pharmaceuticals Inc was a trade of 23,250 Common Stock done . Disclosure was reported to the exchange on Aug. 21, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Aug 2025 | 23,250 | 397,798 (2%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Aug 2025 | 23,250 | 325,500 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 13.22 per share. | 21 Aug 2025 | 10,940 | 386,858 (2%) | 0% | 13.2 | 144,657 | Common Stock |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2025 | 9,362 | 378,957 (2%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2025 | 6,944 | 6,945 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 13.19 per share. | 17 Aug 2025 | 4,409 | 374,548 (2%) | 0% | 13.2 | 58,141 | Common Stock |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2025 | 2,418 | 7,257 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2025 | 113,920 | 113,920 | - | - | Employee Stock Option | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2025 | 113,920 | 113,920 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2025 | 87,500 | 402,574 (2%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 15.69 per share. | 08 Jul 2025 | 32,979 | 369,595 (2%) | 0% | 15.7 | 517,523 | Common Stock |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jun 2025 | 15,625 | 171,876 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jun 2025 | 15,625 | 322,243 (1%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 14.50 per share. | 06 Jun 2025 | 7,169 | 315,074 (1%) | 0% | 14.5 | 103,951 | Common Stock |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 23,250 | 348,750 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 23,250 | 316,617 (1%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 11.88 per share. | 21 May 2025 | 9,999 | 306,618 (1%) | 0% | 11.9 | 118,743 | Common Stock |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2025 | 9,364 | 297,175 (1%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2025 | 6,945 | 13,889 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 11.84 per share. | 17 May 2025 | 3,808 | 293,367 (1%) | 0% | 11.8 | 45,097 | Common Stock |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2025 | 2,419 | 9,675 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 15,625 | 294,480 (1%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 15,625 | 187,501 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 11.97 per share. | 06 Mar 2025 | 6,669 | 287,811 (1%) | 0% | 12.0 | 79,828 | Common Stock |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 372,000 | 372,000 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2025 | 9,363 | 283,959 (1%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2025 | 6,944 | 20,834 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 9.82 per share. | 17 Feb 2025 | 5,104 | 278,855 (1%) | 0% | 9.8 | 50,143 | Common Stock |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2025 | 2,419 | 12,094 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2024 | 15,625 | 282,223 (1%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2024 | 15,625 | 203,126 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 9.75 per share. | 06 Dec 2024 | 7,627 | 274,596 (1%) | 0% | 9.7 | 74,363 | Common Stock |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2024 | 30,198 | 280,998 (1%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2024 | 20,834 | 0 | - | - | Performance Stock Units | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 9.26 per share. | 17 Nov 2024 | 14,400 | 266,598 (1%) | 0% | 9.3 | 133,294 | Common Stock |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2024 | 6,945 | 27,778 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2024 | 2,419 | 14,513 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Sep 2024 | 15,625 | 258,152 (1%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Sep 2024 | 15,625 | 218,751 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 12.19 per share. | 06 Sep 2024 | 7,352 | 250,800 (1%) | 0% | 12.2 | 89,622 | Common Stock |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2024 | 30,195 | 256,742 (1%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2024 | 20,833 | 20,834 | - | - | Performance Stock Units | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 17 Aug 2024 | 14,215 | 242,527 (1%) | 0% | 12.0 | 170,769 | Common Stock |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2024 | 6,944 | 34,723 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2024 | 2,418 | 16,932 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jun 2024 | 15,625 | 234,375 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jun 2024 | 15,625 | 232,012 (1%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 11.53 per share. | 06 Jun 2024 | 7,465 | 224,547 (1%) | 0% | 11.5 | 86,068 | Common Stock |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 51,031 | 238,346 (1%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 11.76 per share. | 17 May 2024 | 21,959 | 216,387 (1%) | 0% | 11.8 | 258,337 | Common Stock |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 20,834 | 0 | - | - | Performance Stock Units | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 20,833 | 41,667 | - | - | Performance Stock Units | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 6,945 | 41,667 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 2,419 | 19,350 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 250,000 | 250,000 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Palleiko Benjamin L. | CFO, CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2024 | 51,029 | 210,117 (1%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Palleiko L. Benjamin | CFO, CBO | Sale of securities on an exchange or to another person at price $ 14.11 per share. | 17 Feb 2024 | 22,802 | 187,315 (1%) | 0% | 14.1 | 321,846 | Common Stock |
| KalVista Pharmaceuticals Inc | Palleiko Benjamin L. | CFO, CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2024 | 20,833 | 20,834 | - | - | Performance Stock Units | |
| KalVista Pharmaceuticals Inc | L. Palleiko Benjamin | CFO, CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2024 | 20,833 | 62,500 | - | - | Performance Stock Units | |
| KalVista Pharmaceuticals Inc | Palleiko L. Benjamin | CFO, CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2024 | 6,944 | 48,612 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | CFO, CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2024 | 2,419 | 21,769 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | L. Palleiko Benjamin | CFO, CBO | Sale of securities on an exchange or to another person at price $ 15.01 per share. | 14 Feb 2024 | 40,855 | 159,088 (0%) | 0% | 15.0 | 613,205 | Common Stock |
| KalVista Pharmaceuticals Inc | Benjamin Palleiko L. | CFO, CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2024 | 87,500 | 199,943 (1%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Palleiko Benjamin L. | CFO, CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2024 | 83,333 | 83,333 | - | - | Performance Stock Units | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | President, CFO, CBO & Secy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2023 | 30,195 | 108,321 (0%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | President, CFO, CBO & Secy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2023 | 20,833 | 0 | - | - | Performance Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | President, CFO, CBO & Secy | Sale of securities on an exchange or to another person at price $ 10.73 per share. | 17 Aug 2023 | 13,067 | 95,254 (0%) | 0% | 10.7 | 140,192 | Common Stock |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | President, CFO, CBO & Secy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2023 | 6,944 | 62,501 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | President, CFO, CBO & Secy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2023 | 2,418 | 26,607 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | President, CFO, CBO & Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 40,000 | 40,000 | - | - | Employee Stock Option (Right to Buy) | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | President, CFO, CBO & Secy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2023 | 6,944 | 76,390 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | CFO, CBO & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2022 | 2,419 | 69,112 (0%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | CFO, CBO & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2022 | 2,419 | 33,863 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | CFO, CBO & Secretary | Sale of securities on an exchange or to another person at price $ 5.44 per share. | 17 Nov 2022 | 722 | 68,390 (0%) | 0% | 5.4 | 3,928 | Common Stock |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | CFO, CBO & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2022 | 2,418 | 67,418 (0%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | CFO, CBO & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2022 | 2,418 | 36,282 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | CFO, CBO & Secretary | Sale of securities on an exchange or to another person at price $ 14.96 per share. | 17 Aug 2022 | 725 | 66,693 (0%) | 0% | 15.0 | 10,847 | Common Stock |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | CFO, CBO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 38,700 | 38,700 | - | - | Restricted Stock Units | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | CFO, CBO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 25,800 | 25,800 | - | - | Employee Stock Option (Right to Buy) | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | CFO, CBO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 75,000 | 75,000 | - | - | Employee Stock Option (Right to Buy) | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | CFO, CBO & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.74 per share. | 23 Feb 2021 | 29,642 | 94,642 (0%) | 0% | 6.7 | 199,787 | Common Stock |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | CFO, CBO & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2021 | 29,642 | 29,611 | - | - | Employee Stock Option (right to buy) | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | CFO, CBO & Secretary | Sale of securities on an exchange or to another person at price $ 33.73 per share. | 23 Feb 2021 | 22,093 | 71,549 (0%) | 0% | 33.7 | 745,274 | Common Stock |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | CFO, CBO & Secretary | Sale of securities on an exchange or to another person at price $ 33.06 per share. | 23 Feb 2021 | 5,293 | 66,256 (0%) | 0% | 33.1 | 174,975 | Common Stock |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | CFO, CBO & Secretary | Sale of securities on an exchange or to another person at price $ 31.77 per share. | 23 Feb 2021 | 1,256 | 65,000 (0%) | 0% | 31.8 | 39,908 | Common Stock |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | CFO, CBO & Secretary | Sale of securities on an exchange or to another person at price $ 35.40 per share. | 23 Feb 2021 | 1,000 | 93,642 (0%) | 0% | 35.4 | 35,404 | Common Stock |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | CFO, CBO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2021 | 37,500 | 37,500 | - | - | Stock Option (right to buy) | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | CFO, CBO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2021 | 32,500 | 65,000 (0%) | 0% | 0 | Common Stock | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | CFO, CBO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2021 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| KalVista Pharmaceuticals Inc | Benjamin L. Palleiko | CFO, CBO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2020 | 85,000 | 85,000 | - | - | Stock Option (right to buy) |